Association of Fas/Apo1 gene promoter (-670 A/G) polymorphism in Tunisian patients with IBD

Table 2 Allelic and genotypic frequency of (-670 A/G) Apo1/Fas gene polymorphisms in patients with inflammatory bowel disease and controls n (%)

ApoI/Fas (-670)	Controls (n = 100)	IBD (n = 164)	UC (n = 59)	CD (n = 105)
Genotypic frequencies
A/A	49 (49)	46 (28.04)c	15 (25.42)b	31 (29.52)a
A/G	32 (32)	70 (42.68)	30 (50.85)	40 (38.10)
G/G	19 (19)	48 (29.26)	14 (23.73)	34 (32.38)
Allelic frequencies
A	130 (70)e	162 (49.39)d	60 (50.84)f	102 (48.57)e
G	70 (35)	166 (50.61)	58 (49.16)	108 (51.43)

^aComparing AA genotype frequencies in CD patients with controls: P corrected = 0.004, OR: 0.44, 95% CI, 0.24 < OR < 0.81;

^bComparing AA genotype frequencies in UC patients with controls: P corrected = 0.0034, OR: 0.35, 95% CI, 0.16 < OR < 0.76;

^cComparing AA genotype frequencies in IBD patients with controls: P corrected = 0.0005, OR: 0.41, 95% CI, 0.23 < OR < 0.70;

^dComparing A/Allele frequencies in IBD patients with controls: P corrected = 0.0004, OR: 0.53, 95% CI, 0.36 < OR < 0.77;

^eComparing A/Allele frequencies in CD patients with controls: P corrected = 0.0007, OR: 0.57, 95% CI, 0.34 < OR < 0.77;

^fComparing A/Allele frequencies in UC patients with controls: P corrected = 0.01, OR: 0.56, 95% CI, 0.34 < OR < 0.91. IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease; OR: Odds ratio; CI: Confidence interval.